What Happened to the Bioresorbable Scaffold Concept
Black Tide or Chernobyl?
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- bioresorbable scaffold
- bioresorbable vascular scaffold
- drug-eluting stent
- coronary artery disease
Since Tamai were the first to launch the fascinating bioresorbable scaffold in 1999, Abbott took the leadership of the proof of concept in human with Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara), a 100% poly-l-lactic acid everolimus-eluting bioresorbable scaffold.1,2 Despite encouraging noninferiority randomized trials during the first 2-year follow-up, these studies showed an increase in-scaffold thrombosis compared with the drug-eluting stent (DES; Xience; Abbott). Unfortunately, the 3-year outcome of ABSORB II (A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions) confirmed by meta-analyses resulted in the end of Absorb BVS use in Europe and the United States.3,4 In September 2017, Absorb BVS was withdrawn from the market, although higher rates of scaffold thrombosis did not result in increased mortality.5 Moreover, 4 other scaffolds with European Conformity …